322
Participants
Start Date
April 1, 2024
Primary Completion Date
October 30, 2025
Study Completion Date
October 30, 2026
Cabotegravir Tablets, for oral use.
Participants randomly assigned to the cabotegravir arm will be instructed to take by mouth a single tablet of cabotegavir 30mg once daily for four weeks.
Cabotegravir Extended-Release Injectable Suspension, for intramuscular use.
Participants will receive 600mg (3mL) CAB LA injections intramuscularly at Month 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24. The injections will be performed in the gluteal muscle by trained healthcare providers at study sites.
Tenofovir disoproxil/Emtricitabine 300mg/200mg fixed-dose combination tablets, for oral use
"* Daily regimen: a single tablet of TDF/FTC every 24 hours, regardless of sexual activity. If PrEP was stopped, resume with two pills of TDF/FTC followed by one pill every 24 hours.~* On-demand regimen: a loading dose of two pills of TDF/FTC 2 to 24 hours before sexual intercourse, a third pill 24 hours after the first drug intake and a fourth pill 24 hours later. In case of daily sexual intercourse, participants will be instructed to take one pill per day until the last sexual intercourse, then to take the two post-exposure pills. If the last dose of TDF/FTC was taken less than one week prior, a leading dose with a single pill of TDF/FTC is sufficient."
Rectal Biopsies
"This intervention concerns only participants involved in the rectal tissue HIV-1 permissibility sub-study.~The proctologist collects ten rectal biopsies at different time points before and after PrEP initiation according to the randomization arm."
Hôpital Hôtel Dieu, Paris
Hôpital Lariboisière, Paris
Hôpital Saint Louis, Paris
Hôpital Saint Antoine, Paris
Hôpital La Pitié Salpêtrière, Paris
Hôpital Necker, Paris
Hôpital Bichat, Paris
Hôpital Tenon, Paris
ANRS, Emerging Infectious Diseases
OTHER_GOV